ImmunoGen, Inc. Announces Webcast of Presentation at the 31st Annual J.P. Morgan Healthcare Conference

Published: Jan 02, 2013

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Daniel Junius, President and CEO, will present at the upcoming 31st Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for 8:00 am PT on January 7, 2013 and will include information about IMGN289, which is on track to become the fourth wholly owned ImmunoGen compound to advance into clinical testing.

Back to news